ASX:AVR Anteris Technologies (AVR) Stock Price, News & Analysis → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free AVR Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend Yield6.45%Price TargetN/A Stock AnalysisStock Analysis Get Anteris Technologies alerts: Email Address Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide About Anteris Technologies Stock (ASX:AVR)Anteris Technologies Ltd, a structural heart company, designs, develops, and commercializes medical devices. The company manufactures and sells ADAPT, a regenerative tissue product. Its lead product is the DurAVRTM, a transcatheter heart valve for the treatment of aortic stenosis. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.Read More Ad Crypto 101 MediaThe Crypto 9-5 Escape PlanA brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide AVR Stock News HeadlinesApril 12, 2024 | finance.yahoo.comThose who invested in Anteris Technologies (ASX:AVR) five years ago are up 292%March 6, 2024 | msn.comASX 200 recoups early losses as major banks push higher, tech stocks pull backMay 10, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” March 6, 2024 | wsj.comAnteris Technologies Ltd.March 2, 2024 | afr.comAnteris Technologies LtdFebruary 29, 2024 | finance.yahoo.comAnteris Technologies Full Year 2023 Earnings: Misses ExpectationsFebruary 8, 2024 | finance.yahoo.comAnteris Technologies Ltd's (ASX:AVR) largest shareholders are retail investors with 50% ownership, institutions own 29%January 20, 2024 | finance.yahoo.comAnteris Technologies Ltd (AVR.XA)May 10, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” December 19, 2023 | msn.comFDA submission looms as Artrya’s AI platform aims to capture the huge cardio diseases marketNovember 29, 2023 | proactiveinvestors.com.auFDA approval for BiVACOR's artificial heart study paves further paths for heart tech innovationNovember 21, 2023 | morningstar.comAnteris Technologies Ltd AVRNovember 21, 2023 | proactiveinvestors.com.auFIVE at FIVE AU: Mining lifts ASX; RBA minutes suggest further rate hikesNovember 20, 2023 | proactiveinvestors.com.auAnteris Technologies fields "excellent" 30-day haemodynamic...Anteris Technologies fields "excellent" 30-day haemodynamic...November 20, 2023 | proactiveinvestors.comAnteris Technologies fields "excellent" 30-day haemodynamic...October 30, 2023 | proactiveinvestors.comAnteris talks market superiority of its biomimetic TAVR valveOctober 17, 2023 | proactiveinvestors.comAnteris Technologies completes DurAVRTM Early Feasibility Study enrolmentOctober 12, 2023 | proactiveinvestors.com.auFIVE at FIVE AU: ASX slips and US markets stumble on higher-than-expected CPISeptember 12, 2023 | au.investing.comAnteris Technologies to present latest clinical data for DurAVR™September 12, 2023 | finance.yahoo.comAnteris Announces Participation at the Cantor Healthcare Conference on Sept 26th 2023August 14, 2023 | businesswire.comDurAVR™ THV Demonstrates Exceptional Results in Second Valve-in-Valve CaseAugust 9, 2023 | finance.yahoo.comAnteris Technologies Commences US Early Feasibility StudyAugust 9, 2023 | finance.yahoo.comAnteris Technologies Commences American Depository Receipt ProgramAugust 1, 2023 | proactiveinvestors.com.auAnteris welcomes successful DurAVR valve-in-valve procedureJuly 31, 2023 | finance.yahoo.comAnteris Technologies Announces First Successful Implantation of DurAVR™ THV in a Valve-in-Valve ProcedureJuly 30, 2023 | au.investing.comAnteris Technologies’ DurAVR heart valve used in life-saving valve-in-valve procedureJune 14, 2023 | finance.yahoo.comAnteris Technologies says latest first-in-human DurAVR™ results are next-levelSee More Headlines Receive AVR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anteris Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:AVR CUSIPN/A CIKN/A Webwww.anteristech.com Phone61 1300 550 310FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($4.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-329.00% Return on Assets-127.62% Debt Debt-to-Equity Ratio8.14 Current Ratio2.60 Quick Ratio4.07 Sales & Book Value Annual Sales$4.11 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueA$1.61 per share Price / BookN/AMiscellaneous Outstanding Shares19,210,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.75 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Wayne G. Paterson (Age 57)CEO, MD & Executive Director Comp: $1.93MMr. Matthew McDonnellChief Financial OfficerMr. David St. DenisChief Operating OfficerDejan TorackiCorporate Development DirectorDr. Chris Meduri M.D.M.P.H., Chief Medical Officer & Member of Medical Advisory BoardMr. Stephen DenaroIndependent Non-Executive Director & Company SecretaryMore ExecutivesKey Competitors4DMedicalASX:4DXAdheriumASX:ADRAinosNASDAQ:AIMDWAllegra Medical TechnologiesASX:AMTAnalyticaASX:ALTView All CompetitorsInsidersJohn SeabergSold 20,000 sharesTotal: $458,800.00 ($22.94/share)Wenyi GuSold 80,500 sharesTotal: $1.63 M ($20.30/share)Wayne PatersonSold 4,167 sharesTotal: $99,174.60 ($23.80/share) This page (ASX:AVR) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe Crypto 9-5 Escape PlanCrypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeHe Is Giving Away BitcoinCrypto Swap ProfitsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anteris Technologies Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
